HMGB3 and ovarian cancer: In ovarian cancer, HMGB3 promotes tumor resistance to chemotherapy drugs by regulating DNA damage response pathways (37), and the MAPK/ERK signaling pathway also contributes to the HMGB3-mediated progression of ovarian cancer (38).